Insider Trading February 27, 2026

Trupanion CFO Disposes of $118,958 in Stock; RSUs Converted on Same Day

Fawwad Qureshi sold 4,645 shares under a Rule 10b5-1 plan as the stock trades near its 52-week low; company posted mixed Q4 2025 results

By Priya Menon TRUP
Trupanion CFO Disposes of $118,958 in Stock; RSUs Converted on Same Day
TRUP

Trupanion's chief financial officer, Fawwad Qureshi, sold 4,645 shares of common stock on February 25, 2026, using a pre-arranged Rule 10b5-1 plan, generating $118,958. That same day he converted 3,750 RSUs to common stock, with 913 shares withheld to satisfy tax withholding valued at $24,377 based on a $26.70 price. The transactions occurred while the stock traded close to its 52-week low of $25.24 and following the company's mixed fourth-quarter 2025 results, which included an EPS miss and a revenue beat.

Key Points

  • CFO Fawwad Qureshi sold 4,645 Trupanion shares on February 25, 2026, at $25.35 - $25.89, netting $118,958.
  • Qureshi exercised 3,750 RSUs the same day; 913 shares were withheld for taxes valued at $24,377 based on $26.70 per share.
  • Trupanion’s Q4 2025 results were mixed: EPS of $0.13 missed the $0.16 estimate (an 18.75% miss) while revenue of $376.9 million rose 12% year-over-year and beat the $375.21 million forecast.

Sale details and trading context

Trupanion NASDAQ:TRUP Chief Financial Officer Fawwad Qureshi executed a sale of 4,645 shares of the company’s common stock on February 25, 2026. The shares were sold at prices between $25.35 and $25.89, producing net proceeds of $118,958. The transaction was reported in a Form 4 filing with the Securities and Exchange Commission and was carried out under a previously adopted Rule 10b5-1 trading plan, which Qureshi put in place on May 19, 2025.

RSU vesting and tax withholding

On the same date, Qureshi also exercised 3,750 restricted stock units (RSUs), converting them into common shares. To satisfy income-tax obligations arising from the RSU vesting, Trupanion withheld 913 shares. Those withheld shares were valued at $24,377 based on a per-share price of $26.70 used for the tax calculation.

Share-price backdrop

The disclosure comes as Trupanion’s stock is trading near a 52-week low of $25.24 and has declined roughly 43% in the past six months. Those price levels form the market backdrop against which the CFO’s sales and RSU conversion took place.

Company results referenced in the filing

Separately, Trupanion reported fourth-quarter results for 2025 that showed a mixed financial picture. The company recorded earnings per share (EPS) of $0.13, below the consensus forecast of $0.16, representing an 18.75% shortfall relative to expectations. Revenue for the quarter was $376.9 million, a 12% increase year-over-year, and slightly above the forecast of $375.21 million.

Analyst and research notes cited

The filing also references an InvestingPro analysis indicating the stock appears undervalued at current levels. Investors seeking additional context are directed to comprehensive Pro Research Reports that cover TRUP and more than 1,400 other U.S. equities.


This report summarizes the insider transaction disclosures and the company’s latest quarterly results as presented in regulatory filings and the company’s financial release.

Risks

  • Market risk - The stock is trading near a 52-week low of $25.24 and has fallen about 43% over six months, indicating continued price pressure that could affect investors and market sentiment.
  • Earnings uncertainty - The company’s Q4 2025 EPS of $0.13 missed expectations, introducing near-term performance uncertainty for equity holders and analysts tracking profitability.
  • Insider liquidity - The reported sale by a senior executive, even when executed under a pre-arranged Rule 10b5-1 plan, may be interpreted by some market participants as an added source of selling pressure or signal of executive liquidity needs affecting the insurance sector.

More from Insider Trading

Marvell Technology President Sells $1.1M in Stock as Shares Trade Near Yearly High Apr 6, 2026 Edward Lampert Sells $58.5 Million in Lands’ End Stock; Company Posts Q4 Shortfall, Announces $100M Buyback Program Apr 6, 2026 NeonC/NeOnc President Buys $153,398 in Stock as Company Advances Financing and Clinical Timeline Apr 6, 2026 Edwards Lifesciences Executive Executes Option Exercise, Sells 1,019 Shares Apr 6, 2026 Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026